6.7.2. management mcrpc - general aspects. selection treatment mcrpc multifactorial general dependent on: previous treatment mhspc non-mhspc;previous treatment nmcrpc mcrpc;quality response pace progression previous treatment;known cross resistance androgen receptor pathway inhibitor (arpi);co-medication known drug interactions (see approved summary product characteristics);known genetic alterations microsatellite instability–high (msi-h)/mismatch repair–deficient (dmmr) status;known histological variants dna repair deficiency (to consider platinum targeted therapy like parpi);local approval status drugs reimbursement situation;available clinical trials;the patient comorbidities. 6.7.2.1. molecular diagnostics metastatic patients offered somatic genomic testing homologous repair mmr defects early on, preferably firstline mcrpc treatment established. testing preferably performed metastatic carcinoma tissue testing primary tumour may also performed. alternatively, still less common, genetic testing circulating tumour dna (ctdna) option used trials. one test, foundationone® liquid cdx, fda approved . defective mmr assessment performed ihc mmr proteins (msh2, msh6, mlh1 pms2) and/or next generation sequencing (ngs) assays . germline testing brca1/2, atm mmr recommended high-risk- particularly metastatic pca clinically indicated. molecular diagnostics performed certified (accredited) institution using standard ngs multiplication procedure (minimum depth coverage 200 x). genes respective exons listed; dna mutations rna needs examined fusions protein expression obtain clinically relevant information. critical asset decision support helping rate mutations according clinical relevance . level 1 evidence use parp-inhibitors reported . microsatellite instability (msi)-high (or mmr deficiency) rare pca, patients, pembrolizumab approved fda could valuable additional treatment option . germline molecular testing discussed section 5.1.6 - genetic testing inherited pca. recommendations germline testing provided section 5.1.7.